The sphingosine-1-phosphate (S1P) receptor modulator, fingolimod (FTY720), has been used for the treatment of patients with relapsing forms of multiple sclerosis, but atrioventricular (AV) conduction block have been reported in some patients after the first dose. The underlying mechanism of this AV node conduction blockade is still not well-understood. In this study, we hypothesize that expression of this particular arrhythmia might be related to a direct effect of FTY720 on AV node rather than a parasympathetic mimetic action. We, therefore, investigated the effect of FTY720 on AV nodal, using in vitro rat model preparation, under both basal as well as ischaemia/reperfusion conditions. We first look at the expression pattern of S1P receptors on the AV node using real-time PCR. Although all three S1P receptor isoforms were expressed in AVN tissues, S1P1 receptor isoform expression level was higher than S1P2 and S1P3. The effect of 25 nM FTY720 on cycle length (CL) was subsequently studied via extracellular potentials recordings. FTY720 caused a mild to moderate prolongation in CL by an average 9% in AVN (n = 10, P < 0.05) preparations. We also show that FTY720 attenuated both ischaemia and reperfusion induced AVN rhythmic disturbance. To our knowledge, these remarkable findings have not been previously reported in the literature, and stress the importance for extensive monitoring period in certain cases, especially in patients taking concurrently AV node blocker agents.

Department of Biology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Cardiovascular Diseases International Clinical Research Center St Anne's University Hospital and Masaryk University Brno Czech Republic

Department of Medical Physics and Biophysics Faculty of Medicine Pavol Jozef Safarik University Kosice Slovak Republic

Department of Pharmacology University of Oxford Oxford and Institute of Cardiovascular Sciences UK

Egom Clinical and Translational Research Services Halifax NS Canada

Zobrazit více v PubMed

Kappos L, Radue EW, O'Connor P, PubMed

Schmouder R, Serra D, Wang Y, PubMed

DiMarco JP, O'Connor P, Cohen JA, PubMed

Gialafos E, Gerakoulis S, Grigoriou A, PubMed PMC

Tellez JO, Dobrzynski H, Greener ID, PubMed

Liu J, Dobrzynski H, Yanni J, PubMed

Cohen JA, Barkhof F, Comi G, PubMed

Karliner JS. Sphingosine kinase regulation and cardioprotection. Cardiovasc Res. 2009; 82: 184–92. PubMed PMC

Peters SLM, Alewijnse AE. Sphingosine‐1‐phosphate signaling in the cardiovascular system. Curr Opin Pharmacol. 2007; 7: 186–92. PubMed

Egom EE, Ke Y, Solaro RJ, PubMed PMC

Egom EE, Ke Y, Musa H, PubMed PMC

Egom EE, Mohamed TM, Mamas MA, PubMed PMC

Mullershausen F, Zecri F, Cetin C, PubMed

Olshansky B, Sabbah HN, Hauptman PJ, PubMed

Gold R, Comi G, Palace J, PubMed PMC

Koyrakh L, Roman MI, Brinkmann V, PubMed

Sanna MG, Liao J, Jo E, PubMed

Brinkmann V. Sphingosine 1‐phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007; 115: 84–105. PubMed

Kurachi Y. G protein regulation of cardiac muscarinic potassium channel. Am J Physiol. 1995; 269: C821–30. PubMed

Yagi Y, Nakamura Y, Kitahara K, PubMed

Sugiyama A. Sensitive and reliable proarrhythmia PubMed PMC

Drici MD, Diochot S, Terrenoire C, PubMed PMC

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

Unbalanced upregulation of ryanodine receptor 2 plays a particular role in early development of daunorubicin cardiomyopathy